Business Description
Kuros Biosciences Ltd
ISIN : CH0325814116
Compare
Compare
Traded in other countries / regions
KURN.SwitzerlandCSBTF.USAKURNz.UKYTSN.Germany IPO Date
2002-10-29Description
Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of innovative products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategy.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.47 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.21 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 9.27 | |||||
| Beneish M-Score | -2.04 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 76.8 | |||||
| 3-Year EBITDA Growth Rate | 6.9 | |||||
| 3-Year EPS without NRI Growth Rate | 6.8 | |||||
| 3-Year FCF Growth Rate | 13.6 | |||||
| 3-Year Book Growth Rate | -15.8 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.73 | |||||
| 9-Day RSI | 46.66 | |||||
| 14-Day RSI | 50.38 | |||||
| 6-1 Month Momentum % | 114.34 | |||||
| 12-1 Month Momentum % | 330.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.06 | |||||
| Quick Ratio | 1.69 | |||||
| Cash Ratio | 1.05 | |||||
| Days Inventory | 156.89 | |||||
| Days Sales Outstanding | 48.54 | |||||
| Days Payable | 47.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.9 | |||||
| Shareholder Yield % | -0.24 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 71.32 | |||||
| Operating Margin % | -39.3 | |||||
| Net Margin % | -40.9 | |||||
| FCF Margin % | -27.32 | |||||
| ROE % | -21.73 | |||||
| ROA % | -17.7 | |||||
| ROIC % | -22.47 | |||||
| ROC (Joel Greenblatt) % | -482.8 | |||||
| ROCE % | -20.26 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.29 | |||||
| PB Ratio | 4.33 | |||||
| Price-to-Tangible-Book | 15.51 | |||||
| EV-to-EBIT | -17.8 | |||||
| EV-to-EBITDA | -22.51 | |||||
| EV-to-Revenue | 6.98 | |||||
| EV-to-FCF | -25.55 | |||||
| Price-to-Median-PS-Value | 0.56 | |||||
| Price-to-Net-Current-Asset-Value | 19.62 | |||||
| Earnings Yield (Greenblatt) % | -5.62 | |||||
| FCF Yield % | -3.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kuros Biosciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 33.564 | ||
| EPS (TTM) (CHF) | -0.38 | ||
| Beta | 0.98 | ||
| Volatility % | 93.51 | ||
| 14-Day RSI | 50.38 | ||
| 14-Day ATR (CHF) | 0.547817 | ||
| 20-Day SMA (CHF) | 7.045 | ||
| 12-1 Month Momentum % | 330.22 | ||
| 52-Week Range (CHF) | 1.25 - 8.4 | ||
| Shares Outstanding (Mil) | 36.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kuros Biosciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kuros Biosciences Ltd Stock Events
| Event | Date | Price(CHF) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kuros Biosciences Ltd Frequently Asked Questions
What is Kuros Biosciences Ltd(XSWX:KURN)'s stock price today?
The current price of XSWX:KURN is CHF6.67. The 52 week high of XSWX:KURN is CHF8.40 and 52 week low is CHF1.25.
When is next earnings date of Kuros Biosciences Ltd(XSWX:KURN)?
The next earnings date of Kuros Biosciences Ltd(XSWX:KURN) is .
Does Kuros Biosciences Ltd(XSWX:KURN) pay dividends? If so, how much?
Kuros Biosciences Ltd(XSWX:KURN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers